{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:13:45Z","timestamp":1791465225529,"version":"4.3.4"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.clinthera.2009.01.013","type":"journal-article","created":{"date-parts":[[2009,2,24]],"date-time":"2009-02-24T14:52:38Z","timestamp":1235487158000},"page":"42-63","source":"Crossref","is-referenced-by-count":49,"title":["Doripenem monohydrate, a broad-spectrum carbapenem antibiotic"],"prefix":"10.1016","volume":"31","author":[{"given":"S.James","family":"Matthews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W.","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.01.013_bib1","series-title":"Doribax (doripenem) [package insert]","year":"2007"},{"key":"10.1016\/j.clinthera.2009.01.013_bib3","series-title":"New Drug Application submitted for investigational antibiotic doripenem [press release]","year":"2007"},{"key":"10.1016\/j.clinthera.2009.01.013_bib4","series-title":"FDA Advisory Committee provides opinion of Doribax for the treatment of hospital-acquired pneumonia [press release]","year":"2008"},{"key":"10.1016\/j.clinthera.2009.01.013_bib5","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/jac\/dkl354","article-title":"Two decades of imipenem therapy","volume":"58","author":"Rodloff","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00003495-199550010-00007","article-title":"Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy","volume":"50","author":"Wiseman","year":"1995","journal-title":"Drug"},{"key":"10.1016\/j.clinthera.2009.01.013_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.8.2.237","article-title":"Ertapenem: The new carbapenem 5 years after first FDA licensing for clinical practice","volume":"8","author":"Burkhardt","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003495-200363090-00005","article-title":"Panipenem\/betamipron","volume":"63","author":"Goa","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2009.01.013_bib9","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2165\/00003495-200262150-00005","article-title":"Biapenem","volume":"62","author":"Perry","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2009.01.013_bib10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0025-7125(16)30037-2","article-title":"Carbapenems","volume":"79","author":"Norrby","year":"1995","journal-title":"Med Clin North Am"},{"issue":"Suppl A","key":"10.1016\/j.clinthera.2009.01.013_bib11","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1093\/jac\/24.suppl_A.1","article-title":"The carbapenems: New broad spectrum beta-lactam antibiotics","volume":"24","author":"Moellering","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1586\/14787210.3.1.23","article-title":"Ertapenem: Review of a new carbapenem","volume":"3","author":"Zhanel","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.clinthera.2009.01.013_bib13","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/jac\/37.5.1034","article-title":"Comparative stability of carbapenem and penem antibiotics to human recombinant dehydropeptidase-1","volume":"37","author":"Mori","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/AAC.42.1.94","article-title":"In vitro and in vivo antibacterial activities of S-4661, a new carbapenem","volume":"42","author":"Tsuji","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib15","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.48.8.3136-3140.2004","article-title":"Activities of doripenem (S-4661 ) against drug-resistant clinical pathogens","volume":"48","author":"Jones","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7164\/antibiotics.49.199","article-title":"A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relation- ships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems","volume":"49","author":"Iso","year":"1996","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.clinthera.2009.01.013_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1128\/AAC.00910-07","article-title":"Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis","volume":"52","author":"Credito","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1569-9056(08)60787-3","article-title":"Urinary bactericidal activity of doripenem versus levofloxacin in patients with complicated urinary tract infections or pyelonephritis","volume":"7","author":"Wagenlehner","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.clinthera.2009.01.013_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/13543784.11.4.529","article-title":"Recent developments in carbapenems","volume":"11","author":"Bonfigho","year":"2002","journal-title":"Expert Opm Investig Drugs"},{"key":"10.1016\/j.clinthera.2009.01.013_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/jac\/36.1.53","article-title":"Potent activity of meropenem against Escherichia coll arising from its simultaneous binding to penicillin-binding proteins 2 and 3","volume":"36","author":"Sumita","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1128\/AAC.16.3.325","article-title":"Competition of beta-lactam antibiotics for the penicillin-binding proteins of Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella aerogenes, Proteus rettgeri, and Escherichia coli. Comparison with antibacterial activity and effects upon bacterial morphology","volume":"16","author":"Curtis","year":"1979","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jac\/12.2.119","article-title":"Mode of action of ceftazidime: Affinity for the penicillin-binding proteins of Escherichia coli K1 2, Pseudomonas aeruginosa and Staphylococcus aureus","volume":"12","author":"Hayes","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib23","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/AAC.01529-07","article-title":"Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coll and Pseudomonas aeruginosa","volume":"52","author":"Davies","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib24","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jac\/dkn004","article-title":"Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x","volume":"61","author":"Davies","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib25","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1128\/AAC.48.4.1384-1396.2004","article-title":"In vitro antimicrobial activity of doripenem, a new carbapenem","volume":"48","author":"Ge","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib26","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1469-0691.2005.01271.x","article-title":"Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003)","volume":"11","author":"Fritsche","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2009.01.013_bib27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jac\/dkh298","article-title":"Doripenem (S-4661), a novel carbapenem: Comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations","volume":"54","author":"Jones","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1179\/joc.2002.14.2.155","article-title":"In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections","volume":"14","author":"Nomura","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jac\/46.3.471","article-title":"In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens","volume":"46","author":"Mikamo","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000007276","article-title":"Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens","volume":"46","author":"Watanabe","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1016\/j.clinthera.2009.01.013_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1179\/joc.2002.14.3.227","article-title":"Comparative in vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections","volume":"14","author":"Pelak","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1179\/joc.2002.14.5.483","article-title":"In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics","volume":"14","author":"Friedland","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0732-8893(02)00387-5","article-title":"Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections","volume":"43","author":"Pelak","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2009.01.013_bib34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1046\/j.1469-0691.2002.00461.x","article-title":"Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections","volume":"8","author":"Hicks","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2009.01.013_bib35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0924-8579(02)00129-2","article-title":"In vitro activity of ertapenem (MK-0826) against multidrug resistant Streptococcus pneumoniae compared with 13 other antimicrobials","volume":"20","author":"Hilliard","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2009.01.013_bib36","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/jac\/dkh445","article-title":"In vitro activity of ertapenem against selected respiratory pathogens","volume":"54","author":"Marchese","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0732-8893(02)00395-4","article-title":"In vitro activity of ertapenem against bacterial isolates from cancer patients","volume":"43","author":"Rolston","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2009.01.013_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jac\/48.1.23","article-title":"Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria","volume":"48","author":"Fuchs","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib39","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1128\/AAC.45.6.1915-1918.2001","article-title":"In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers","volume":"45","author":"Fuchs","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib40","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/AAC.45.6.1860-1867.2001","article-title":"In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia","volume":"45","author":"Livermore","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib41","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/jac\/dki134","article-title":"Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: Tentative disc diffusion criteria and quality control","volume":"55","author":"Brown","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.diagmicrobio.2004.02.003","article-title":"Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: Report of year five (2003)","volume":"49","author":"Rhomberg","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2009.01.013_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2003.05.010","article-title":"Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of the 2001 data from 15 United States medical centres","volume":"23","author":"Rhomberg","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2009.01.013_bib44","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0732-8893(03)00112-3","article-title":"Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: Report from the MYSTIC Program (2002) in North America","volume":"47","author":"Rhomberg","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2009.01.013_bib45","doi-asserted-by":"crossref","first-page":"44134417","DOI":"10.1128\/AAC.49.10.4413-4417.2005","article-title":"In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates","volume":"49","author":"Wexler","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib46","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1128\/AAC.44.9.2389-2394.2000","article-title":"Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections","volume":"44","author":"Goldstein","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0732-8893(02)00430-3","article-title":"Ertapenem (MK-0826), a new carbapenem: Comparative in vitro activity against clinically significant anaerobes","volume":"44","author":"Aldridge","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2009.01.013_bib48","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1469-0691.2005.01233.x","article-title":"Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece","volume":"11","author":"Papaparaskevas","year":"2005","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.01.013_bib49","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1086\/341932","article-title":"General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacilhn-tazobactam","volume":"35","author":"Goldstein","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2009.01.013_bib50","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/jac\/48.5.641","article-title":"Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections","volume":"48","author":"Goldstein","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib51","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/jac\/dkl052","article-title":"Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999\u20132003","volume":"57","author":"Roberts","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijantimicag.2006.01.011","article-title":"Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria","volume":"28","author":"Behra-Miellet","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2009.01.013_bib53","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1128\/AAC.49.8.3239-3250.2005","article-title":"In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem","volume":"49","author":"Koga","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib54","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.46.1.220-224.2002","article-title":"In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds","volume":"46","author":"Hoellman","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib55","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/jac\/dkh218","article-title":"In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics","volume":"53","author":"Alhambra","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib56","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jac\/dkg404","article-title":"Ertapenem, the first of a new group of carbapenems","volume":"52","author":"Shah","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3201\/eid0702.010238","article-title":"Controversies about extended-spectrum and AmpC beta-lactamases","volume":"7","author":"Thomson","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.clinthera.2009.01.013_bib58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diagmicrobio.2004.12.008","article-title":"Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms","volume":"52","author":"Jones","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2009.01.013_bib59","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jac\/dkg375","article-title":"Properties and potential of ertapenem","volume":"52","author":"Livermore","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib60","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2009.01.013_bib61","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1600-0463.2005.apm1130306.x","article-title":"Carbapenem resistance mechanisms in Pseudomonas aeruginosa: Alterations of ponn OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates","volume":"113","author":"El Amin","year":"2005","journal-title":"APMIS"},{"key":"10.1016\/j.clinthera.2009.01.013_bib62","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.48.8.3086-3092.2004","article-title":"Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib63","series-title":"Presented at: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"S-4661, a new carbapenem: IV. Pharmacokinetics in healthy volunteers","author":"Nakashima","year":"1994"},{"key":"10.1016\/j.clinthera.2009.01.013_bib64","series-title":"Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Doripenem: A phase 1 study to evaluate safety, tolerabihty and pharmacokinetics in a Western healthy volunteer population","author":"Thye","year":"2003"},{"key":"10.1016\/j.clinthera.2009.01.013_bib65","series-title":"Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Population pharmacokinetics (PPK) of doripenem (DOR)","author":"Van Wart","year":"2004"},{"key":"10.1016\/j.clinthera.2009.01.013_bib66","series-title":"Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"A phase 1 open-label controlled study to evaluate the safety, tolera-bihty, and pharmacokinetics (PK) of doripenem (DOR) administered intravenously to subjects with renal impairment","author":"Floren","year":"2004"},{"key":"10.1016\/j.clinthera.2009.01.013_bib67","series-title":"Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"A phase I, double-blind, placebo-controlled study to determine the safety, tolerabihty, and pharmacokinetics (PK) of prolonged-infusion regimens of doripenem (DOR) in healthy subjects","author":"Floren","year":"2004"},{"key":"10.1016\/j.clinthera.2009.01.013_bib68","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/jac\/dkm371","article-title":"Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients","volume":"60","author":"Ikawa","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.01.013_bib69","first-page":"104","article-title":"Phase I study of doripenem, a new carbapenem antibiotic for injection in healthy volunteers [in Japanese]","volume":"53","author":"Nakashima","year":"2005","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib70","series-title":"Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Pharmacokinetics and pharmacodynamics of S-4661, new parenteral carbapenem antibiotic","author":"Shiba","year":"1997"},{"key":"10.1016\/j.clinthera.2009.01.013_bib71","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1128\/AAC.00424-08","article-title":"Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men","volume":"52","author":"Cinilo","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.01.013_bib72","first-page":"136","article-title":"Effect of probenecid on pharmacokinetics of doripenem in healthy male volunteers [in Japanese]","volume":"53","author":"Shiba","year":"2005","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib73","series-title":"Presented at: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Pharmacokinetics of S-4661, new parenteral carbapenem antibiotic, 1000 mg multiple-dose administration in healthy male volunteers","author":"Nakashima","year":"1998"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.01.013_bib74","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1086\/518137","article-title":"Pharmacokinetics and pharmacodynamics of antimicrobials","volume":"45","author":"Drusano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2009.01.013_bib75","series-title":"Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"In vivo pharmacodynamic activity of a new carbapenem, doripemen (DOR), against multiple bacteria in a murine thigh infection model","author":"Andes","year":"2003"},{"key":"10.1016\/j.clinthera.2009.01.013_bib76","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01252-07","article-title":"In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures","volume":"52","author":"Kim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib77","series-title":"Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Use of pharmacokinetics-pharmacodynamics (PK-PD) as decision support for phase 3 dose justification for doripenem","author":"Ambrose","year":"2004"},{"key":"10.1016\/j.clinthera.2009.01.013_bib78","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.49.9.3944-3947.2005","article-title":"Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem","volume":"49","author":"Bhavnani","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib79","series-title":"Presented at: 36th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"In vitro postantibiotic effect and in vivo antimicrobial activity of novel carbapenem, S-4661","author":"Totsuka","year":"1996"},{"key":"10.1016\/j.clinthera.2009.01.013_bib80","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/03602530701690341","article-title":"Interaction between valproic acid and carbapenem antibiotics","volume":"39","author":"Mon","year":"2007","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.clinthera.2009.01.013_bib81","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10156-005-0402-2","article-title":"Study of the synergism between carbapenems and vancomycin orteicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan","volume":"11","author":"Kobayashi","year":"2005","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.clinthera.2009.01.013_bib82","series-title":"Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"In-vitro interactions of doripenem with other antimicrobial agents","author":"Mushtaq","year":"2005"},{"key":"10.1016\/j.clinthera.2009.01.013_bib83","series-title":"Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Clinical studies of S-4661, new parenteral carbapenem antibiotic, in chronic respiratory tract infections","author":"Saito","year":"1997"},{"key":"10.1016\/j.clinthera.2009.01.013_bib84","series-title":"Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Clinical studies of S-4661, new parenteral carbapenem antibiotic, in complicated urinary tract infections","author":"Arakawa","year":"1997"},{"key":"10.1016\/j.clinthera.2009.01.013_bib85","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/CCM.0b013e3181691b99","article-title":"Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study","volume":"36","author":"Chastre","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2009.01.013_bib86","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1185\/03007990802179255","article-title":"Efficacy and safety of doripenem versus piperacillin\/ tazobactam in nosocomial pneumonia: A randomized, open-label, multicenter study","volume":"24","author":"R\u00e9a-Neto","year":"2008","journal-title":"Curr Med Res Opm"},{"key":"10.1016\/j.clinthera.2009.01.013_bib87","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.clinthera.2008.04.019","article-title":"Efficacy and tolerabihty of IV doripenem versus meropenem in adults with complicated intraabdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study","volume":"30","author":"Lucasti","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2009.01.013_bib88","series-title":"Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Doripenem versus meropenem for the treatment of complicated intraabdominal infections","author":"Malafaia","year":"2006"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.01.013_bib89","first-page":"S212","article-title":"Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis","volume":"13","author":"Naber","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2009.01.013_bib90","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/01.CCM.0000055380.86458.1E","article-title":"Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome","volume":"31","author":"Luna","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2009.01.013_bib91","series-title":"Primaxin IV (imipenem and cilasta-tin for injection) [package insert]","year":"2007"},{"key":"10.1016\/j.clinthera.2009.01.013_bib92","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1086\/340740","article-title":"Practical aspects of choosing an antibiotic for patients with a reported allergy to an antibiotic","volume":"35","author":"Robinson","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2009.01.013_bib93","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1592\/phco.27.1.137","article-title":"Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy","volume":"27","author":"Prescott","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2009.01.013_bib94","first-page":"S3","article-title":"An overview of harms associated with beta-lactam antimicrobials: Where do the carbapenems fit in?","volume":"12","author":"Owens","year":"2008","journal-title":"CritCare."},{"key":"10.1016\/j.clinthera.2009.01.013_bib95","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.tox.2006.02.004","article-title":"Absence of convulsive ha- bili ty of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics","volume":"222","author":"Horiuchi","year":"2006","journal-title":"Toxicology"},{"key":"10.1016\/j.clinthera.2009.01.013_bib96","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.clinthera.2008.04.001","article-title":"Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia","volume":"30","author":"Merchant","year":"2008","journal-title":"Clin Their"},{"key":"10.1016\/j.clinthera.2009.01.013_bib97","series-title":"Drug Topics Red Book","year":"2007"},{"key":"10.1016\/j.clinthera.2009.01.013_bib98","series-title":"Drug Topics Red Book (Update)","year":"2008"},{"key":"10.1016\/j.clinthera.2009.01.013_bib99","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T06:55:53Z","timestamp":1558162553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809000277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0149291809000277"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.01.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}